| |
CEF11  |
|
|
| Cat. No. |
Size |
Price |
Figures |
|---|
RP11773-1 mg
| 1 mg | $ 71.25 | MSDS: 20080715041121 (PDF)
References:
- Steven NM, et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. May 1997; 185(9): 1605-1617.
|
|---|
| Full Name | |
| Alias |
Epstein-Barr Virus BMLF1 (280-288), CEF11; CEF-11; Epstein-Barr Virus BMLF1; Epstein-Barr Virus BMLF1 |
Sequence
(one-letter code) |
GLCTLVAML | Sequence
(three-letter code) | {GLY}{LEU}{CYS}{THR}{LEU}{VAL}{ALA}{MET}{LEU} |
|---|
| Description | Epstein-Barr virus (EBV) is a herpesvirus commonly associated with several malignancies, particularly in immunocompromised hosts. Epstein-Barr virus (EBV) is a ubiquitous gammaherpesvirus that can establish both latent and lytic infections. EBV is commonly associated with several malignant diseases, including Burkitt's lymphoma (BL), Hodgkin's disease (HD), undifferentiated nasopharyngeal carcinoma (NPC), and various T-cell lymphomas. It is also frequently detected in immunocompromised hosts, especially in immunosuppressed allograft recipients who develop posttransplantation lymphoproliferative disorder.
HLA A2.1-restricted epitope from Epstein-Barr Virus lytic protein BMLF1 (280-288). |
|---|
| Formula | C40H73N9O11S2 |
|---|
| M.W. | 920.2 |
|---|
| Purity | > 95% |
|---|
| Storage | Stora at -20°C. |
|
